Our research aims to enhance the use of mesenchymal stromal cells (MSCs) as therapies for acute lung diseases, particularly acute respiratory distress syndrome (ARDS). MSCs have significant potential as a treatment, but despite promising preclinical results, clinical success has been limited. A key factor contributing to this is the complex interaction between MSCs and the host environment in inflammatory conditions, which influences cell function and efficacy.

We investigate how MSCs respond to various disease environments, including factors such as inflammatory cytokines and infections, and how these interactions can impact the therapeutic capacity of the cells. Our goal is to identify patient groups and conditions where MSC treatment is most effective, as well as to optimize the survival and function of the cells in acute lung diseases.